{"name":"Margitta Worm","slug":"margitta-worm","ticker":"","exchange":"","domain":"","description":"Margitta Worm is a specialty pharma company focused on developing and commercializing niche pharmaceutical products. The company has a limited public profile, with two key drugs in its portfolio, including a marketed product and an early-stage compound.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dimethindene","genericName":"dimetindene","slug":"dimetindene","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Dimethindene","genericName":"dimetindene","slug":"dimetindene","phase":"phase_1","mechanism":"Dimethindene works by blocking the histamine H1 receptor, which is involved in allergic reactions and other histamine-related processes.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQcmF4LU9MUGhEUjJubG5OQWItczZ4ang1VmVHRTZGMnU3VExlTWFLa01YNExENXpMUHhPMTdPX1dSaDdsQ3VMQzlVSzVXZWFNXzlRQ3MwS1Badk5RcHhZeFlrODVweUFoRUJoMGZycmdpUkZjcGVJQXJJYUZ0Zi1wYTRsR1M0eHVfRGRtVmM2d0VwMGpOZlBNVHRsZ2hPRGRtczVVMmd3YXhVckNjenF4Nk1iMVVOWXBTQS1zV1N6SQ?oc=5","date":"2025-09-19","type":"pipeline","source":"Healio","summary":"Fish-, shellfish-induced anaphylaxis cases in Europe differ in age, region - Healio","headline":"Fish-, shellfish-induced anaphylaxis cases in Europe differ in age, region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFB0WUZsbmxnZlpVTjl6N1Z0c1hjaHpLaXozTTJYZF9DRWc5TWlrbFYxSGpkcTdSNzBQODdmakhmNkhnZGxNRkxJQTNNSlptbDhhanhMYzB0TGFablNRSDhyLTZhd3hKN2ZMVmpKZWppNmoxQQ?oc=5","date":"2024-07-30","type":"trial","source":"Wiley","summary":"Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials - Wiley","headline":"Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from tw","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOQUNqdVFEUUE1ck40cWdocjQ1UGV4Ml9lM19lLUpqWWRzVHpoelpmWWI2U2UzY196cWxVc0RMelpwM0YtRjVWbHpTX2xYM2lvVlFteUdVTk0zNEJPV3lELWU4YUtDOGp6eWpCcXMxRVdYTTRacjJkU19QbVptdVJ4aG9adzN1NG5yLU94b3NjUnc3dWVhZVFkeGlDanAxZ1RiMVhJ?oc=5","date":"2024-01-17","type":"pipeline","source":"Healio","summary":"Insect venom causes most occupational anaphylaxis - Healio","headline":"Insect venom causes most occupational anaphylaxis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBXNnRka1U5cU96Y2lqR0E3QkRRM3JDbFFzNlRsSmhCM3Zfc3FLdGtOR1NsbXFnMGFabU5QTENkeHFNc0dBdVNzWGlsQjhDVVhmZzFQVldR?oc=5","date":"2020-10-30","type":"regulatory","source":"Medscape","summary":"Delgocitinib Successful for Hand Eczema in Phase 2b Trial - Medscape","headline":"Delgocitinib Successful for Hand Eczema in Phase 2b Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OLTRPSW13OHMxRm54cjdEbUhWM0daOUVKZF9sMExJaVVnZTA5aW90WTIweWNscnZiUktVTGs1dlhqS3BMdERzRjdxRFRXNnBmZ3pzYUlaWmRHLVVUM004?oc=5","date":"2016-12-15","type":"trial","source":"NEJM","summary":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis - NEJM","headline":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}